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Abstract 
 
Biofilms are a complex group of microbial cells that adheres to the exo-polysaccharide matrix 
present on the surface of medical devices. Biofilm associated infections in the medical devices 
pose a serious problem to the public health and adversely affect the function of the device. 
Medical implants used in oral and orthopedic surgery are fabricated using alloys such as stainless 
steel and titanium. The biological behavior, likeOsseo-integration and its antibacterial activity, 
essentially depends on both the chemical composition and the morphology of the surface of the 
device. Surface treatment of medical implants by various physical and chemical techniques are 
attempted in order to improve their surface properties so as to facilitate bio-integration and 
prevent bacterial adhesion.The potential source of infection of the surrounding tissue and 
antimicrobial strategiesare from bacteria adherent to or in a biofilm onthe implant which should 
prevent both biofilm formation and tissue colonization.This article provides an overview of 
bacterial biofilm formation and methods adopted for the inhibition of bacterial adhesion on 
medical implants 
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 1. Introduction 
 
The skyrocketing increase in number of joint replacement surgeries and their associated failures 
have raised serious concern in the field of medicine. Amongst various reasons, failure of medical 
devices due to infection has resulted in increase in number of revision surgeries, and sometimes 
fatality.Biomaterial associated infection (BAI) is due to the bacteria in the skin of the patients. 
These infections are mostly caused by staphylococci, in particular by Staphylococcus 
epidermidis and Staphylococcus aureus, and by streptococci, Gram-negative bacilli, enterococci 
and anaerobes like Propionibacterium acnes. It also involves high medical costs and the 
insurance companies have procured the medical device related infections are preventable in 
USA. Infection is seen to occur either immediately after the surgery or post-surgery and the 
reasons for the same are such as i) implant surface, ii) surgical theater, surgical equipment’s and 
surgeon iii) from the patient iv) contaminated disinfectants v) and from other persons. Apart 
from mal-nutrient and obesity, the patients with clinical problems such as rheumatoid arthritis, 
diabetes mellitus and immune-compromised status are frequently in more risk of infection. In the 
cases where the infections are not treatable using conventional techniques such as short and long 
term antibiotics treatment, two stage revision surgeries is preferred. In the first stage the infected 
implant is removed and the patient is treated for infection and in the second stage a new device is 
implanted. Thus understanding the causes for the biofilm formation and associated and its 
prevention has become one of the most important field in medical device research. 
 
Biofilms are the most major form of microbial life and that are biologically active matrix of cells 
and extra-cellular substances in association with a solid surface (1). Biofilms are attached to a 
substrate and consists of many bacteria implanted in an organic polymeric substance. The extra-
cellular polysaccharides (EPS) are an insoluble and slimy secretion that is released by bacterial 
cells, encases millions of adjoining cells in a well-organized and structured matrix (2). The EPS 
encapsulation offers three important advantages to cells that reside in biofilms. First, the EPS can 
assist in dissemination of nutrients that are necessary for cell growth (3). Second, due to the 
diverse composition of charged polysaccharide groups that can easily bind nutrient molecules, 
EPS traps the external nutrients that are required for cell sustenance and growth (3). Third, the 
cells that are encapsulated in the EPS matrix receive better protection from external 
environmental stresses compared to planktonic bacteria (4). The advantages of biofilm formation 
includes protection from antibiotics (5), disinfectants (6) and from dynamic environments (7). 
Biofilm growth is governed by number of physical, chemical and biological factors. 
 
Development of a biofilm involves five stages where in the first stage the cells get adhered to the 
surface and it produces extracellular polysaccharide which leads to the formation of biofilm. 
Once the bacterium is matured, they get detached and start dispersing single cells due to the 
unfavorable environmental conditions. The dispersed cells swims away from the biofilm and get 
adhered on the favorable surface matrix.  The biofilm production causes serious threats in the 
medical field by infecting the medical implants and devices. In order to overcome all these ill- 
effects several surface modifications and treatments are attemptedto decrease the growth of 
biofilm formation on the medical implants. This review attempts to report some of the 
biomaterial associated infections and discusses in detail on the anti-biofilm coatings to overcome 
the challenges posed by the bacterial adhesion. The section 1.1 deals with the various aspects of 
biofilm formation ,while section 2 deals with the approaches to develop   anti-biofilm  and 
section 3 discusses on various  biofilm models that inhibits bacterial formation. 
 
1.1. Biofilm formation  
Biofilms are medically important, accounting for over 80% of microbial infections in the body, 
including prostheses and internal fixation devices. In vitro study has shown that Pseudomonas 
aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis can easily form biofilms 
on stainless steel and titanium orthopedic screws. Further invitro study demonstrated that S. 
aureus, S. epidermidis and P. aeruginosa possess strong forces of adhesion to foreign bodies. 
 
The biofilm comprises of three layers and Fig, 1 shows the different layers of biofilm. The first 
layer , the linking or conditioning film which is attached to the surface of the tissue or 
biomaterial, the second is the biofilm base which contains microbes and the surface film acts as 
an outer layer where planktonic organisms are  released as free floating and spreads to the 
surrounding compartment (8 -11).  
 
1.2. Mechanism of biofilm formation in medical implants: 
 
1.2.1. Initiation of biofilm formation: 
 
The primary adhesion stage of biofilm involves the quick adhesion of microbes to the 
surface of the medical devices and proliferation of cells (Fig 2). During this formation of biofilm 
there are various factors which are responsible for the initial adhesion of the microbes such as 
polarity, London –van der Waal’s forces (Fig 3) and hydrophobic interactions (12). There are 
various bacterial surface attached proteins(not clear) which contribute to the initial adhesion and 
biofilm formation. The biofilm consists of proteins, electrolytes and some unidentified molecules 
(8, 13). A polysaccharide structure known as capsular polysaccharide/adhesion (PS/A) leads to 
the initial adhesion and slime production (14). Initial attachment of S.epidermidis to a polymer 
surface may be mediated by AtlE, a surface associated autolysin (15).The biofilm associated 
protein Bap leads to the biofilm formation in S.epidermidis (16). 
 
1.2.2 Aggregation and biofilm maturation: 
The adherence of the bacteria to the inert surface leads to the formation of stable micro-colony. 
Bacterial cell proliferation and intercellular adhesion takes place once the microbes adhered to 
the surface of the implants. A polysaccharide antigen named polysaccharide intercellular 
adhesion (PIA) leads to the intercellular adhesion and biofilm accumulation in Staphylococci 
(17). During this accumulation phase, the microbes multiply and forms several layered cell 
clusters on the surface of the foreign body. Micro colonies further develop into macro colonies 
and are enclosed by an extracellular polysaccharide matrix (18). Extra polysaccharide substances 
(EPS) are produced in this phase which is responsible for the binding and cell adhesion to the 
surface (18, 19). The EPS matrix acts as a barrier and protects the microbes during adverse 
conditions. Within the EPS matrix intercellular signaling or quorum sensing takes place. Cell-
cell signaling has been demonstrated to play a role in the cell attachment and detachment from 
biofilms (20, 21). Quorum sensing is based on the process of auto induction (22) and it provides 
a mechanism for self-organization and regulation of microbial cells (23). Microorganisms use the 
quorum sensing to coordinate their communal behavior such as biofilm formation, motility and 
production of EPS (24). For example, in S. aureus, the Agr quorum sensing system regulates the 
production of virulence factors that enhance attachment to host cells, defensive factors to avoid 
elimination by the host, and factors that promote bacterial internalization and host cell apoptosis 
(25, 26). In gram negative bacteria, cell communication is achieved by the activity of acylated 
homoserine lactones (AHLs) (27). The accumulation of AHL in developing biofilm causes the 
transformation of individual cells from the planktonic to the biofilm phenotype and coordinates 
the behavior (28). The biofilm reaches a critical mass and generates planktonic microorganisms. 
These free floating organisms escape the biofilm and colonize on other surfaces. These bacterial 
cells becomes inactive or die due to the lack of nutrients, decrease in pH or accumulation of toxic 
metabolic by products (29). In this phase, matured biofilm is formed and the microorganisms are 
ready for the disruption from the surface. 
 
1.2.3. Dispersal of biofilm cells: 
 
The bacterial cells from the biofilm disperse the cells from the surface and migrate because of 
the depletion in nutrients. Finally the microorganism detaches from the macro-colony and moves 
into the bloodstream and spreads infections and embolic complications. This detachment can be 
due to various factors including fluid dynamics and shear effects of the bulk fluid (30). The 
surface hydrophobicity characteristic of newly divided daughter cells disperses spontaneously 
either from E. coli or P. aeruginosa biofilms differs substantially from the chemo stat- intact 
biofilm or re-suspended biofilm cells (31). The dispersal mode differs in each bacteria and it 
affects the morphological characteristics of the organisms. P. fluorescens disperses and 
recolonizes a surface after approximately 5 h, V. parahaemolyticus after 4 h, and V. harveyi 
recolonizes only after 2 h (32). This process paves a path for cells to migrate from deeply 
colonized areas which has less surface adsorbed nutrients to the surface which is rich in 
nutrients. These aggregate cells retain certain biofilm characteristics and antimicrobial 
properties. The cells which have been detached due to undesirable condition revert back quickly 
and float freely in the surface. Some of these released microorganisms have a tendency to  
relocate  and restart the biofilm process (33). Inside bacterial biofilm there is a high density of 
bacterial population that activates a cell-density dependent mechanism called quorum sensing 
(QS). There are QS systems in both Gram positive and Gram negative bacterial populations and 
these regulate the expression of adhesion mechanisms and virulent factors. It has been 
demonstrated that QS also control the differentiation of the biofilm and can lead to killing of the 
leukocytes in some Gram negative bacteria.  Due to the protection offered by the extracellular 
polymeric substances produced by bacteria themselves and the changed physiology of the 
biofilm bacteria, it is difficult for the immune system and antibiotics to eradicate the bacterial 
cells embedded in the biofilm, and, therefore, the biofilm infection becomes chronic. Further, the 
biofilm bacterial cells usually elicit less inflammatory response than the planktonic bacterial cells 
which makes it difficult for clinicians to diagnose such an infection. 
 
1.3. Biofilm formation on biomedical implants: 
 
Microbial infections in the biomedical implants pose a serious threat in modern medicine. A 
Biofilm infection remains a major cause of failure in biomaterial implants. All medical devices 
are susceptible to colonization of microbial infection. Medicaldevices are responsible for about 
60–70% of hospital-acquired infections, particularly in critically ill patients (34, 35). It is known 
that bacterial biofilms can colonize the surfacesof both tissues and implanted medical devices. 
Bacterial biofilm infection consequentlyleads to tissue destruction, systemic dissemination of the 
pathogen and dysfunction of the device, resulting in serious illness and death (36). The main 
microorganisms responsiblefor biofilm formation on indwelling medical devices are, Gram-
positive (Enterococcusfaecalis, Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus viridans)and Gram negative (Escherichia coli, Klebsiellapneumoniae, Proteus 
mirabilis, Pseudomonas aeruginosa) bacteria, as well as yeasts (37). Titanium implants pre-
seeded with S. epidermidis or carrying a pre-grown S. epidermidis biofilm, the bacteria were 
mostly present in the surrounding tissue and co-localized with macrophages. S. epidermidis were 
cultured from the tissue in large numbers, shows that many of the bacteria were viable. Thus, a 
contaminated implant can be a reservoir for infection of the surrounding tissue where bacteria 
can reside intracellular (178).Biomedical device associated infections are resistant to immune 
defense mechanisms and are difficult to treat with antimicrobial agents because the organisms 
are encased within a protected microenvironment hampering the prevention and treatment of 
established bacterial associated infections (13). Biomaterial associated infection occurs despite 
of many preventive measures and intervention with antibiotics often is ineffective. Diluted 
susceptibility of sessile bacteria present in biofilms and poor penetration of antibiotics through 
the biofilm matrix are considered the predominant causes of the limited efficacy of antibiotics 
against biomaterial associated infection. Therefore the treatment often requires prolonged 
antibiotic therapy, because as antibiotics alone they are able to only suppress infection and not 
completely eliminate the infection caused. So in many cases ultimately antibiotics needs to be 
combined with adequate surgical intervention (178).The bacterium which grows on the medical 
implants forms a slimy layer of biofilm and the simplest way to treat the infections is to treat and 
modify the surface of the medical device. Several research efforts have been made to eliminate 
and reduce the infections in the medical implants. Microbial infections have been observed in 
almost all medical devices or implants like prosthetic heart valves, orthopedic implants, dental 
implants (Fig 4)intravascular catheters, artificial pump, left ventricular assist devices, cardiac 
pacemakers, vascular prostheses, cerebrospinal fluid shunts, urinary catheters, voice prostheses, 
ocular prostheses and contact lenses, and intrauterine contraceptive devices (35, 38, 39) ( 
Table1). In non-surgical indwelling medical devices, such as central venous and urinarycatheters, 
colonization of biofilm may originate either from the skin at the point of insertion, or around the 
catheter once implanted. As for surgical devices, tissue damage and clot formation associated 
with surgical implantation are associated with the enhanced rates of microbial biofilm 
colonization (21, 40-42). Upon implantation, there is a competition between integration of the 
material into the surrounding tissue and adhesion of bacteria to the implant surface (43). 
 
For a successful implant, tissue integration should occur prior to significant bacterial adhesion, 
thereby preventing the bacterial colonization at the implant. All medical devices or tissue 
engineering constructs are susceptible to microbial colonization and infection (44). Upon a 
strong adhesion to the surface, the bacterium begins to secreteand collect proteins, 
polysaccharides and DNA to formulate a biofilm (45, 46). Biofilminfections constitute a number 
of clinical challenges, including disease, chronic inflammation, impaired wound healing, rapidly 
acquired antibiotic resistance, and the spread of infectious emboli (34, 36, and 47). Infections 
related with biomaterial inorthopedic applications, lead to a condition of osteomyelitis with 
disturbing effects on bone and the environmental soft tissues. Such infection does not seem to 
respond to any conventional antibiotic treatments (48-51). Micro-organisms on the implant 
surface that contains adhesins which favors attachment leads to surface tension or 
hydrophobicity [non-specific factors]. In fracture fixation, infections occurs in   a) Pre-operative 
cases [Open Trauma], b) Intra-operative cases [Insertion of Fixation devices] c) Post-Operative 
Cases [Wound Healing]. In orthopedic surgery,the infection rate is reported more in stainless 
steel when compared to titanium alloys as the later favors easy formation of soft tissue (52). In 
revision surgery of prosthetic hips and knees, the presence of bacteria in peri-implant tissue 
indeed is a risk factor for reinfection. Bacteria may even persist in large numbers within host 
cells, including in macrophages (178). 
It has been reported that many bacteria can cause prosthesis-related infections, such as S. aureus, 
including methicillin-resistant strain (MRSA), coagulase-negative staphylococci (CNS) (e.g. S. 
epidermidis, S. haemolyticus, S hominis, S warneri), Propionibacterium acnes, P. aeruginosa, 
Haemophilusinfluenzae, Providencia, Enterococci, Streptococcus viridans, Escherichia coli, 
Citrobacter, Lactobacillus, Acinetobacter, Serratiamarcescens, Klebsiellapneumoniae, 
andCorynebacterium. Amongst these pathogens, S. aureus and coagulase- negative 
staphylococci are the most common bacteria responsible for prosthesis-related infections, 
accounting for approximately half of the infections or more. Infections occurring in the first three 
months after surgery are usually caused by virulent microorganisms such as S. aureus, whereas 
delayed infections (3-24 months after surgery) are in most of the cases caused by low virulent 
microorganisms such as coagulase-negative staphylococci. Poly-saccharide intercellular adhesin 
(PIA) produced by staphylococci has been demonstrated to be a crucial virulent factor that helps 
staphylococci to form biofilm in implants or orthopedic biomaterials. The other important 
phenomenon in the pathogenesis of biomaterial associated infection is the survival of bacteria in 
the tissue surrounding implants, are observed. Though the macrophages and granulocytes are 
present around an implant, the microorganisms cannot be cleared, due to the frustrated 
phagocytosis caused by the implantation of a biomaterial. 
 
2. Novel anti biofilm control approaches in medical implants:  
 
A variety of approaches have proven to be effective in reducing biofilm related infections by 
preventing the bacterial adhesion on medical devices, at least in high risk populations (53). The 
prevention of biofilm formation in medical implants can becontrolled by following various novel 
emergent strategies like Quorum sensing quenchers, polymer coatings, antimicrobial coatings, 
enzyme mediated approaches, phage therapy, immunotherapy, nano structured coatings, surface 
modifications and bio surfactants (Table 2). 
 
Bacterial adherence to silicone has been found to be significantly higher than to polyurethane or 
Teflon_R (54). Host factors, such as fibronectin, fibrinogen or platelets may be deposited on the 
foreign body material and provide specific ligands for bacterial adhesions (55). Bacterial biofilm 
infections on the medical implants can be prevented by device coatings, device immersion, anti-
septic irrigation of the surgical site, antibiotic loaded cements in orthopedic surgery (42) and 
antibiotic catheter lock therapy containing vancomycin and heparin (56) or minocycline and 
EDTA (57). In antibiotic catheter lock therapy, a concentrated antibiotic solution is placed in a 
catheter in a volume adequate to fill the lumen. The catheter is then “locked” into place for an 
extended period while the catheter is not in use, with the goal of preventing it from becoming 
colonized and thereby reducing the risk of infection (41). Impregnation of catheter surfaces with 
antiseptics (58) or antibiotics (42) has been shown to delay bacterial colonization. Antibiotic lock 
therapy was used to prevent catheter related blood stream infections in hemodialysis patients (59, 
60), identified a new lipid based formulations and incorporated antibiotics for anti-infective 
action in vascular grafts to prevent bacterial colonization. Bi-functional poly ethylene glycol 
with integrin active peptide RGD (arginine-glycine-aspartic acid) coatings on titanium oxide has 
the potential to prevent biofilm formation and supports the tissue integration (61). 
 
2.1. Prevention of biofilm by surface modification and coatings: 
 
Bio-inspired coatings are developed to reduce the bacterial adhesion and to prevent the microbial 
biofilm formation in the medical implants. Various strategies are made to produce anti-biofilm 
coatings using natural and synthetic materials. 
 
2.1.1. Antibiotic - Hydroxyapatite based coatings: 
 
The advantage of local delivery of antibiotics for a prolonged use of drug therapy inhibits 
medical implant-related infections. It is applicable in lower dose and less susceptibility to 
promote antibiotic resistance and has long term sustained release for different drugs with 
different kinetics (62). The antibiotics used widely in controlled-release of drugs are gentamicin, 
amoxicillin, vancomycin, cephalothin and tobramycin. Among these drugs, the most recently 
used drug carrier for antibiotics and antibacterial material is polymethylmethacrylate (PMMA) 
(63). Equally the effect of controlled release of antibiotics at a very high rate was observed in 
biodegradable drug carriers like poly lactic- co- glycolic acid (PLGA), poly lactic acid (PLA) 
and poly ethylene glycol (PEG). Price et al., 1996 examined the bacterial growth invitro by 
coating biodegradable polymer PLGA with the antibiotic gentamicin in orthopedic implants 
which showed 99% efficiency to control the bacterial adhesion. Hydroxyapatite coating is most 
widely applied in the medical field. The synthetic hydroxyapatite and calcium phosphates are 
used for bone implants due to the ability to support the growth of new bone tissue and induces 
bone-tissue integration. These coatings can be altered by surface-adsorbed antibiotics by 
immersion in antibiotic solutions. Sol-gel spin-coating process is used to coat titanium alloy with 
HA and evaluated its efficiency as drug carrier by immersion with gentamicinesulphate (64). 
Enriched implant fixation also acts as an indicator to a reduced rate of infection. In the largest 
part of cases, the implants are preferably removed after fracture healing and excessive fixation 
makes this removal hard or even unbearable (65, 66). 
 
 
2.1.2. Antiseptic based Coatings: 
 
Antiseptics plays a major role in reducing the potential for enhancing resistant bacterial strains, 
compared to the use of antibiotics in implants (67, 68). Development of implant fixation and 
contaminated prophylaxis in external fixation in goat studies proved the efficacy of HA coatings 
containing antiseptic substances. The successful coating of chlorhexidine and chloroxylenol for 
intramedullary implants of a rabbit model was used in local drug delivery as a coating for 
catheters application (35, 69).  
 
2.1.3. Nano -Silver Coatings: 
 
Silver is known to have antimicrobial activity (70, 71) and by encapsulating silver nanoparticles 
either in implant coatings or directly with cements is used for joint replacement applications. 
Nano silver coatings have been prominently applied to several medical devices like catheters, 
and wound dressings. The use of polymer coatings with antibacterial substance allows a choice 
of material to be used to adapt the kinetics by varying the formulation of the coating 
components. Rameshbabu et al.,2006, have used microwave processing of nanosized silver 
substituted HA particles (30 nm) and studied the effect of silver concentration (0.5–3%) on the 
antimicrobial effect against E. coli and S. aureus. Silver nanoparticles on the surface of medical 
implants prevent bacterial adhesion and formation of biofilm. The nanoparticles are either 
deposited directly on the surface of the device or applied in a polymeric surface coating. The 
silver is slowly released from the surface, thereby killing the bacteria present near the surface 
(72). As a result silver has been incorporated into the surface of a variety of medical devices, 
such as vascular, urinary and peritoneal catheters, vascular grafts, prosthetic heart valve sewing 
rings, surgical sutures and fracture-fixation devices (38, 73). A broad spectrum of pathogens 
found at implant sites, including P. aeruginosa, E. coli, S. aureus, and S.epidermidis, can be 
affected (40). A suggested mechanism considers that Ag+ reacts withand disrupts the function of 
bacterial cell membranes and crucial metabolic proteins and enzymes by binding to DNA and 
thiol groups in proteins (74). Nano silver crystalline HA demonstrates improved biological 
efficiency in terms of osteoblast adhesion, proliferation, Osseo-integration, and formation of new 
bone on its surface (75). 
 
2.1.4. Photoactive based coatings: 
 
A material which quickens a chemical reaction during its irradiation of an 
electromagnetic wave is a photo catalyst material. In this condition, the most considered 
semiconductor photo catalyst after the detection of its behavior is Anatase TiO2 (76). In order to 
yield an effective ion process, the semiconductors were exposed upon with ultraviolet radiation, 
in which the photon energy generates its excitation. These ions are efficient in degrading organic 
contaminations and provide an antimicrobial function (77-78). 
The photoactive Titanium films are obtained by electrophoretic deposition (79), plasma ion 
implantation (78, 80), direct oxidation of Ti (81), sol-gel and dip coating (82) and arc-ion plating 
methods. Similarly, the effect of UV light pre-treatment of titanium surface with its 
osteoconductive capacity reflects that on post-exposure of UV radiation, the hydrophilic surface 
was transformed to super-hydrophilic surface (83). There is also no substantial difference 
between the antimicrobial behavior of TiO2 – coated and uncoated CP-Ti implants; i.e., both 
materials reveals antibacterial activity without cytotoxicity on L-929 cells. Moreover, to deposit 
anatasetitania film on the surface of titanium implants, plasma ion implantation and post-
annealing process are used (84). Later those implants were illuminated by UV radiation before in 
vitro testing using pluripotent mesenchymal precursor C2C12 cells. These observations show the 
effect of super hydrophilicity of TiO2 on cell behavior and bone formation (80). 
 
2.1.5. Nanostructured Coatings: 
 
Nanomaterials show great promise in the fabrication of novel biomedical implants and its 
coatings. Nanofilms, nanocoatings, and nanostructured surfaces are being widely used for 
biomedical applications (85). Several mechanisms in controlled drug release from surface of 
implanted devices coated with nanostructure biofilm yields more advantages over conventional 
coatings. However, as this approach has not been used for orthopedic coatings, the usage of 
inorganic nanocoatings as drug delivery systems plays a major role in stents. Inorganic 
nanocoatings are also used for drug delivery in implantable sensors and a device has been 
achieved by fabrication of silicon nanowires.  (86, 87). In addition,  the loading and release 
efficiency from titania nanotube, using bovine serum albumin and lysozyme as model proteins 
are also being investigated as   nanotubulartitania does not cause chronic inflammation or 
fibrosis invivo (88). Ceramic nanoparticles enhance bioactivity while the polymer component 
improves the fracture toughness and adhesion to the substrate without the need of high-
temperature firing (89). Diamond nanoparticles or nanodiamonds (NDs) have recently attained 
significant interest for local drug release in the form of coatings. Owing to superior physical 
properties and biocompatibility,diamond-based nanostructures have emerged as an alternative 
promising material for biomedical applications such as diamond films for robust implant 
coatings (90). 
 
2.2. Treatment of medical implant associated infections: 
 
Biomaterials associated infections can be treated by prolonged and high- dose of 
antibiotic therapy. Bacterial biofilms are inherently resistant to antimicrobial agents andtend to 
be significantly less responsive to antibiotics and antimicrobial stressors than planktonic 
organisms of the same species (9, 34). Antibiotic treatment of bacterialendocarditis was shown to 
be more successful when serum antibiotic levels were held at least tenfold above the minimal 
bactericidal concentration (91) but even with 8 weeks of treatment, few patients have been cured 
by antimicrobial therapy alone (92). Thecombination of rifampicin and a fluoroquinone has 
proven especially successful in the treatment of various S. aureus biofilm infections ranging 
from infections of orthopaedic prostheses (13) to right-heart endocarditis (93). Replacement or 
removal of an infected indwelling medical device, combined with systemic antibiotic and/or 
antifungal therapy, is the most effective treatment in most settings (94). For managing indwelling 
medical device infections in non-surgery patients, long-term antimicrobial suppressive therapy 
remains the only option (41). Recent reviews summarize current recommended practices for the 
treatment of infections of prosthetic joints (94), arterial prostheses (95) , vascular catheters (44), 
prosthetic heart valves (96), central nervous system shunts (Yogev andBisno in (96), pacemakers 
and defibrillators (96), endotracheal and tracheotomy tubes (97), and hemodialysis and 
peritoneal hardware (98), as well as treatment of foreign body infections of the urinary tract (99). 
 
2.3. Treatment of medical implants associated infections with nanoparticles: 
 
The use of nanoparticles is another new approach against biofilm mediated infections. For the 
treatment of infections, various nanomaterials such as silver nanoparticles, zinc oxide 
nanoparticles, gold nanoparticles, carbon nanotubes are developed for the direct use as 
biomedical devices. Nanoparticles bind to bacterial cell walls causing membrane disruption 
through direct interactions or through free radical production (100). Mammalian cells are able to 
phagocytose nanoparticles and can subsequently degrade these particles by lysozomal fusion 
(101) and reduce toxicity and free radical damage. This property allows for the selection of 
nanoparticles to promotetissue forming cell functions and inhibits bacterial infection. 
Nanomaterials possessing super paramagnetic properties such as iron oxide nanoparticles can be 
directed insitu using a magnetic field to the site of infection (102). Iron oxide nanoparticles have 
been used for numerous biomedical applications, such as for the separation of biomolecules from 
bacteria or delivery of antibiotics and drugs, with simultaneous enhancement of MRI contrast 
(103-105). A magnetic field can increase the uptake of magnetic nanoparticles into bacterial 
biofilms. Using mixed methods of targeting and imaging, super paramagnetic iron oxide 
nanoparticles (SPION) could further improve the treatment of infections (102). Nanomaterials 
such as ZnO, titanium dioxide (TiO2), polymers and carbon nanotubes can reduce microbial 
adhesion, proliferation, and biofilm growth due to their antimicrobial properties. These 
nanomaterials have an ability to mimic the constituent properties of natural tissues thus 
nanotechnology is considered as a promising tool in tissue engineering and biomaterials. Medical 
devices are being designed through the incorporation of carbon nanotubes into sensors to serve 
as feedback loops to detect bacteria and release antibiotics only when needed (106, 107). 
 
3. Biofilm Models:  
 
Biofilm model systems are essential to gain a better understanding of the mechanisms involved 
in biofilm formation and resistance. In order to increase the knowledge concerning biofilm 
biology, biofilm model systems are used for the study of the complex communities under 
controlled conditions are indispensable (108-110). 
 
3.1. In vitro biofilm model systems: 
 
3.1.1. i. Microtiter plate based method: 
 
Several investigators commonly use microtiter plate method as this technique enlightens the 
biofilm which is either grown in the walls of the microtiter plate or at the bottom or even at the 
surface of a coupon placed in the wells of the plate. Further, a batch- reactor in a closed system is 
used which avoids the inflow and outflow during the process (109). It is used to discriminate 
biofilm-deficient mutants from wild type strains (112) and to monitor the antimicrobial and anti-
biofilm effects of different antibiotics, chemicals, plant extracts and disinfectants (113,114). 
Later, a deep investigation on the effects of modification, coating or impregnation of materials 
on different biofilm developing stages can be performed using this method (115, 116). Finally, 
the MTP based systems, were found to differ with its multiple parameters in addition to the 
composition of growth media, incubating temperatures, humid control, observance of shear stress 
for O2 and CO2 concentrations (117, 118). 
 In addition to the MTP-based assay, the encapsulation of inert paramagnetic beads is 
included in a medium during the formation of biofilm and it is available as ‘Biofilm Ring Test’. 
To collect the non-encapsulated beads, a magnet is used in to a single spot which is later 
measured through particular image algorithms. This is generally used to study the kinetics of 
biofilm formation of Listeria monocytogenes, E.coli, Staphylococcuscarnosusand 
Staphylococcus xylosus, (119) to measure the biofilm matrix mechanismson 
Leuconostocmesenteroides biofilm formation (120). It can also be used to assess the antibiotics 
effects on Pseudomonas aeruginosa biofilms (121), to relate the formation of biofilm amongst 
Campylobacter coli and Campylobacter jejuni (122). 
 
3.1.2. ii. Flow Displacement Method: 
 
Compared to the conventional MTP -based method, an open system which is used for the 
growth of the medium with nutrients is added and the waste-products are removed. The flow 
displacement system is sub-classified into ‘Continuous flow stirred tank reactor’ or the ‘plug 
flow reactor’ methodology. During its major comparison, the continuous flow reactor has a 
perfect mixing and made identical for the rate at which the growth medium and is considered as 
the ‘feed rate’. In this method, when the dilution rate is higher than the doubling time of the 
microorganisms in the reactor, planktonic cells are eroded out of the reactor and only the sessile 
cells attached to a surface will remain and have the ability to multiply. But in plug flow reactor, 
the influent moves as a single ‘plug’ in the axial direction through diffusion (Heersink in (109) 
(109)). 
 
3.1.3. iii. Modified Robbins Method [MRD]: 
 
Modified Robbins method uses a device which is used to immediately produce and forms the 
biofilm in the fluid. This can be constructed using a stainless steel or plastics containing a 
number of separate ports in a linear array through a channel of rectangular cross-section (123, 
124). Later, this device is filled with a suspension of microorganisms and is reversed over to 
enhance the adhesion of planktonic cells to thediscs. As soon as the devices are filled with 
suspensions, the tubing at the inlet and outlet side is fixed off and the remaining suspension in 
the tubing at the inlet is flushed out through the bypass. Next to this phase, the devices are 
exploded leading to loosening of clamp and continuous flow of the growth medium on the disc 
from the pump. Thus biofilm is formed on the discs (124). In addition, its application has the 
potential of antibiotic lock therapy for biofilm removal from colonized surfaces (125-127). 
 
3.1.4. iv. CDC Biofilm Reactor: 
 
A glass vessel containing polyethylene lid supporting eight removable polypropylene 
rods are used in CDC biofilm reactor. In this reactor, each rod can grasp three removable 
coupons on which biofilm formation occurs and the coupon is perpendicular to the rotating baffle 
(128, 129). A magnetic stirrer is placed in the center of the device providing a continuous flow of 
nutrients by means of a peristaltic pump over the colonized surfaces (130). This device is 
recognized as a perfect tool to grow 
 
Pseudomonas aeruginosa biofilms with high shear and continuous flow. Later, 24 
similarbiofilms can be designed instantaneously as the setup allows for the easy removal of discs 
during the experiment (131, 132). Currently this CDC reactor was used to investigate the activity 
of high dose vancomycin, moxiflaxacin in combination with other antibiotics against 
Staphylococcus aureus biofilms (133). Also, its application includes with the testing of materials 
coated with antimicrobial compounds and the simulation of deposition of urinary catheters (134, 
135). 
 
3.1.5. v. Cell-culture and Micro fluidic based models: 
 
Biotic surfaces are also an important source for the formation of biofilms compared to abiotic 
surfaces, in which human cell lines are made to mimic the in vivo situation. A major form of 
mucosal biofilm is formed by Candida albicans, by inoculating it in reconstituted human 
epithelium(RHE), forming a structure on the top of the epithelial layer, representing that they can 
serve as in vitro biofilm model systems (136). Immortalized human microvascular endothelial 
cells were coated on glass slidesembedded in a parallel plate flow chamber which is perfused 
with a C. albicans suspension. Many models were used to study the interaction of human cells 
with bacterial biofilms. Commonly used are Pseudomonas aeruginosa biofilms on airway 
epithelial cells (137), Streptococcus gallolyticus biofilms grown on endothelial cells (138), 
biofilms of entero-hemorrhagic E.coli on HeLa cells (139, 140) and 
Stenotrophomonasmaltophiliabiofilms formed on cystic fibrosis from bronchial cells (141). The 
cell-culturebased models not only allow screening microbiological biofilm formation, but also 
used to assess the damage occurred upon the human cells by this process. 
 
Fabrication of these devices for the formation of biofilm requires photolithography, 
which is a process of transferring a pattern from a mask into a thin layer of photosensitive 
polymer and later onto the surface of a substrate (142). In microfluidic devices, the sizes of the 
channels used are model-dependent and it is in the range of 50-500Qm wide and 30-250Qm deep 
and its length also varies from 5 to 40mm. However, a ‘well plate microfluidic’ device is used to 
allow high-throughput evaluation of biofilms in a microfluidic device (143-145). This device 
consists of micro-channels combined into a MTP. Pneumatic pressure pushes fresh medium 
through the micro-channel, from an inlet containing fresh medium to an outlet containing spent 
medium. 
 
3.2. In-vivo Biofilm models: 
 
3.2.1. i. Caenorhabditiselegans and Sub-cutaneous foreign body infection models: 
 
C.eleganssystems were also used to emphasis on the virulence for the effect ofparticular 
chemical compounds on the survival of the worms. A study by Darby et al., 2002 (146), on 
C.elegans with Yerstiniapestis showed that, Y.pestis biofilm formation in the head and mouth 
region prevented C. elegans feeding. By evaluating a transposon-insertion mutant bank, it also 
revealed that Y. pestis genes are involved in the formation of a polysaccharide matrix which is 
required for the biofilm formation. Also different microorganisms were tested in the C. elegans 
system like, S. epidermidis and S. aureus (147) and Xenorhabdusnematophilia (148). The C. 
elegans model is also used to recognize a host gene which is needed for the bacterial adhesion. 
 
These subcutaneous models were developed in hamsters, mice, rabbits, guinea pigs and rats. A 
foreign particle is inserted into the subcutaneous pockets and a biofilm is allowed to mature on 
the implant. Mostly, this process is carried on S. aureus and S.epidermidis, but other 
microorganisms like E.coli, P. aeruginosa and C. albicanswerealso reported. Thus the 
inflammatory response associated with surgery may prevent biofilm formation in less virulent 
organisms like C. albicans and for these microorganisms, it is recommended with the use of 
immunosuppressive drugs. In addition to this, there is also a chance for the materials to 
contaminate either in pre-implantation or in post-implantation (52, 149, 150). Hence this 
subcutaneous model is compatible to investigate the effect of substrates on the biofilm formation 
(151-153). Based on subcutaneous implantation, perforated cylinders made of Teflon, has glass 
beads or other materials to enhance the surface area for biofilm formation were used as a tissue 
cage (154). This model has an advantage that the microbial cells are recovered from the fluid 
inside the tissue cage without the need for the explanation (155). This model is used to study the 
immune responses from the host (156) in vivo gene expression (157), the efficacy of specific 
antimicrobial agents (158) and to regulate the role of genes in establishing bio-film associated 
infections (159, 160). 
 
3.2.2. ii. Respiratory and Urinary Tract infection systems: 
 
In respiratory tract models, P. aeruginosa cells were improved from sputum of CF [cystic 
Fibrosis] patients which is in the form of biofilm structure with colonies encapsulated in a matrix 
material, it contains P. aeruginosa quorum sensing molecules in the ratio found in in vitro grown 
biofilms. This method confirms the hypothetical condition of the respiratory tract infections were 
related to biofilms (9). Bacteria enclosed in agar beads were used in laboratory animals which 
resulted in proliferation and chronic infection with histological damage parallel to that observed 
in patients with cystic fibrosis or chronic obstructive pulmonary diseases. Infections are 
categorized by reliable numbers of organisms with a steady-state immunological response were 
also added in agar-bead based models (Sokol in (161)). The majority of investigations involving 
microorganisms for respiratory tract infections were carried with P.aeruginosa and 
Burkholderiacepacia organisms (8, 162-164). To mimic the infections detected in diffuse 
panbronchiolitis (165), a model of severe P. aeruginosa respiratory tract infection model has 
been developed. In this model a plastic intravenous catheter is coated with P. aeruginosa and is 
inserted in the trachea through the mouth (165-167), in which the infection is controlled to the 
lungs. Similarly, a pulmonary infection model without syntheticencapsulation is developed. 
Animals are infected intratracheally with a small amount of planktonic culture of an alginate-
producing P.aeruginosa strain (168). 
 
In surgical and non-surgical urinary tract methods, a first system was designed with zinc 
which was implanted in the rat’s bladder, preceded by transvesical inoculation with Proteus 
mirabilis. It is used to validate the significance of biofilm and matrix formation to develop the 
urinary tract models (169). In this condition, a catheterized rabbit model was advanced to study 
catheter-associated urinary tract infections, which is used to study the effect of various 
antibiotics on E. coli biofilms developing on these catheters and on adjacent tissues (169-172). 
Models were designed in rabbits to study the effect of coating urinary stents with RNAIII-
inhibiting peptide [RIP] against S. aureus infections (173). In vivo models have been used to 
investigate the ability of other coated catheters in avoiding urinary tract infections (174, 175). 
 
3.2.3. iii. ENT infection models: 
 
Several models have been established to study the biofilm-associated infections in ear, 
nose and throat. The traditional design of Chinchilla model made a definite establishment of a 
relation between otitis medium and biofilm, by allowing direct visualization of the biofilm on the 
middle-ear mucosa following transbullar injection with Haemophilus influenza (176, 177). Later, 
this system was used to determine the efficacyof S. pneumoniae to form nasopharyngeal and 
middle-ear mucosal biofilms with transbullar inoculation. 
 
4. Conclusion: 
 
Implant associated microbial infection poses a serious menace and remains a major cause for the 
failure of biomaterial implants. Various bioactive coatings with the polymers have the potential 
to reduce and eliminate the microbial adhesion of biofilm in the prosthetic biomaterial devices. 
Biofilm model systems are essential and it provides the enhanced understanding in the 
mechanism of biofilm formation. These systems can be used for the investigation and 
comparison of various biofilm control treatments and biomaterial device design modifications. 
Further research efforts on novel control strategies of biofilm and various innovative surface 
modifying approaches for the prevention of bacterial infection in medical implants should be 
enhanced and investigated in order to provide a unique shield against biofilm infection. 
 
4.1. Prospects of Future works: 
 
As the surface and material topography of biomaterials have an important effect on microbial 
colonization, an extensive research on effect of various surface compositions and topography on 
the formation of biofilm is required to combat this problem. In addition, the efficient control of 
biofilm associated infections in medical implant will require an intensive effort to develop 
therapeutic agents that target the morphology of the biofilm and interrupts the cell signaling. 
Thus the key for the success of antibiofilm approaches may hinge upon a more complete 
understanding of the biofilm phenotype and surface modification in the medical implant along 
with the therapeutics which acts as quorum quenchers/ inhibits and prevents the formation of 
bacterial adhesion and its related infections. 
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Fig 1: Layers of Biofilm 
 
 
 
 
 
Fig 2: Schematic representation of biofilm formation 
 
 
 
 
 
Fig 3: Steps involved in biofilm formation and the factors responsible for the biofilm 
 
 
 
 
Fig 4: Biofilm formation in dental implant 
 
 
 
Table 1: Biofilm producing microorganism in medical implants 
 
Medical 
implants 
Biofilm producing microorganism References 
      
Artificial voice 
prostheses  
Candida albicans, Streptococcus mitis, Bryers, 2008 
Rodrigues et al., 
2007 
  Streptococcus  salivarius,  Rothia  
  dentrocariosa, Candida tropicalis, Streptococcus  
  sobrinus,Staphylococcusepidermidis,Stomatococcus  
  mucilaginous       
Artificial hip 
prosthesis 
Coagulase-negative  Staphylococci,  β-hemolytic  
  Streptococci,  enterococci,  Proteus mirabilis, Darouiche, 2001 
  Bacterioides  species, Staphylococcus  
  aureus,Streptococcus,Escherichia  coli,  
  Pseudomonas aeruginosa    
   
Replacement 
joints 
 S. aureus and S. epidermidis   Bryers, 2008 
Prosthetic heart 
valves 
Streptococcus viridans, coagulase-negative Rodrigues et al., 
2007 
  Staphylococci, enterococci, Staphylococcus aureus  
Cardiac pace 
makers 
S.aureus      Darouiche, 2001 
CSF shunts  S.aureus,S.epidermidis,Enterococcu
s 
  Darouiche, 2001 
Endotracheal 
tubes 
 S. aureus, S. epidermidis, C. albicans,P.aeruginosa Darouiche, 2001
Urinary 
catheters 
 S. epidermidis, K. pneumoniae, E. faecalis, Proteus  
  mirabilis      Bryers, 2008; 
Darouiche, 2001; 
Rodrigues et al., 
2007 
Peritoneal 
dialysis catheters 
Streptococci, Staphylococci   Bryers, 2008; 
Darouiche, 2001; 
Rodrigues et al., 
2007 
Central venous 
catheters 
S.  epidermidis,  S.  aureus,  E.  faecalis,  K.  
  pneumoniae, P. aeruginosa, C. albicans  Bryers, 2008; 
Darouiche, 2001; 
Rodrigues et al., 
2007 
Contact 
lenses 
 P. aeruginosa and Gram-positive cocci  Bryers, 2008; 
Darouiche, 2001; 
Rodrigues et al., 
2007 
Dental 
implants 
 Acidogenic Gram-positive cocci (e.g.   
  Streptococcus),Gram-negative anaerobic oral Bryers, 2008; 
Darouiche, 2001; 
Rodrigues et al., 
2007 
  bacteria       
Implanted 
prosthetic 
devices for 
S. aureus and S. epidermidis    
erectile 
dysfunction 
       Bryers, 2008; 
Darouiche, 2001; 
Rodrigues et al., 
2007 
    
Intrauterine  Micrococcus sp.,Enterococcus sp., Candida Rodrigues et al., 
2007 
contraceptive 
devices 
albicans, Group B Streptococci  
      
Orthopaedic 
implants 
Hemolytic streptococci, Enterococci, P. mirabilis, Rodrigues et al., 
2007 
  Bacteroidessp.,P.aeruginosa, E. coli.   
Breast 
implants 
 S. aureus, Enterococcusand S. epidermidis  Bryers, 2008 
 
  
 
 
 
Table 2: Novel anti biofilm approaches (Maureen et al., 2008) 
 
Approaches  Mechanism of action Target Reference
      
QS interference  QS interruption RNAIII  Cirioni et al 2003;
RNA III-inhibiting peptide   synthesis  Balaban et al, 2005. 
(RIP)          
Impairing adhesion  Anti-adhesive activity; Microbial Rodrigues et al  
Biosurfactants,includin
g  interference with
Adhesio
n  2006.   
RC14 biosurfactant  initial bacterial      
‘surlactin’.  attachment.  Gene encoding Baveja et al .,2004; 
Furanone compounds  Reducing adhesion adhesion and Hume et al.,2004. 
   and colonization. slime production    
Diterpenoids (salvipisone Destabilising biofilm   Kuz´ma et al.,  
and aethiopinone)  matrix allowing Biofilm matrix 2007; Walencka et 
   detachment +/ altering +/ bacterial cell al., 2007   
   bacterial cell surface surface     
   hydrophobicity.      
Targeting slime  Inhibiting bacterial PIA biosynthetic Burton et al., 2006
formation  cell wall synthesis and enzymes; GlmU    
N-acetyl-D glucosamine- PIA formation enzyme  
1-phosphate acetyl      Pe´rez-Giraldo et al 
transferase (GlmU)  Reducing production   1997;Aslam et al  
inhibitors(N-substituted  of extracellular Extracellular 2007   
maleimides).  polysaccharide matrix polymeric matrix    
N-acetylcysteine (NAC) and promoting      
   disruption of mature Biofilm  Curtin &Donlan  
   biofilm  exopolysacchari 2006; Cerca et al 
Bacteriophage therapy;  Lytic activity on de and biofilm 2007   
phage K & Bacteriophage biofilm cells cells     
456          
Immunotherapy         
FN binding receptor  Blocking adhesion FN binding Bryers& Ratner
monoclonal antibodies    receptor  2004.   
(MAbs).   Inhibition of  PIA PIA  McKenney et al.,
Anti-PIA antibodies  formation.    2000.   
   Blocking adhesion Fbe Pei et al 1999; Pei 
Surface binding      & Flock 2001;  
protein/Fbe antibodies  Inhibiting  Aap Rennermalm et al., 
   accumulation and   2004.   
Anti-Aap domain B  intercellular adhesion   Rohde et al., 2005; 
antiserum Aap antibodies     Sun et al.,2005;  
       Rohde et al., 2007. 
Enzymatic removal  Enzymatic removal Biofilm matrix Johansen et al.,
Oxido reductases & and disinfection of   1997.   
Polysaccharide  biofilm       
hydrolyzing enzymes    Peptidoglycan Wu et al., 2003.  
Lysostaphin(staphylolytic Disruption of biofilm pentaglycine    
endopeptidase)  
matrix and killing 
ofreleased bacteria 
Interpeptidecross-
bridges of 
Staphylococcal 
cell wall.    
 
 
 
 
 
      
   Kaplan et al., 2004; 
Dispersin B (DspB) Enzymatic   Donelli et al.,2007. 
 degradation of cell      
 Bound β-1,N-acetyl-D-    
 exopolysaccharide glucosamine.    
Serratiopeptidase adhesin, an essential Biofilm slime Selan et al., 1993;  
 component of the matrix  Mecikoglu et al.,  
 biofilm polymeric   2006.   
 matrix.      
 Induces biofilm      
 degradation via      
 Proteolytic      
 activity,also enhances      
 antibiotic activity      
Immunomodulation Reversal of Macrophages Boelens et al
Interferon γ Macrophage   .,2000a, b.   
 deactivation in the      
 vicinity of implanted      
 Biomaterial      
